Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.
Guida M, Bartolomeo N, Quaresmini D, Quaglino P, Madonna G, Pigozzo J, Di Giacomo AM, Minisini AM, Tucci M, Spagnolo F, Occelli M, Ridolfi L, Queirolo P, De Risi I, Valente M, Sciacovelli AM, Chiarion Sileni V, Ascierto PA, Stigliano L, Strippoli S. Guida M, et al. Among authors: bartolomeo n. J Transl Med. 2022 Apr 5;20(1):159. doi: 10.1186/s12967-022-03359-x. J Transl Med. 2022. PMID: 35382857 Free PMC article.
Sporadic melanoma in South-Eastern Italy: the impact of melanocortin 1 receptor (MC1R) polymorphism analysis in low-risk people and report of three novel variants.
Guida S, Bartolomeo N, Zanna PT, Grieco C, Maida I, De Summa S, Tommasi S, Guida M, Azzariti A, Foti C, Filotico R, Guida G. Guida S, et al. Among authors: bartolomeo n. Arch Dermatol Res. 2015 Aug;307(6):495-503. doi: 10.1007/s00403-015-1552-4. Epub 2015 Mar 4. Arch Dermatol Res. 2015. PMID: 25736238
Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors.
Guida M, Strippoli S, Ferretta A, Bartolomeo N, Porcelli L, Maida I, Azzariti A, Tommasi S, Grieco C, Guida S, Albano A, Lorusso V, Guida G. Guida M, et al. Among authors: bartolomeo n. Pigment Cell Melanoma Res. 2016 Nov;29(6):679-687. doi: 10.1111/pcmr.12516. Pigment Cell Melanoma Res. 2016. PMID: 27540956
The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma.
Guida M, Bartolomeo N, De Risi I, Fucci L, Armenio A, Filannino R, Ruggieri E, Macina F, Traversa M, Nardone A, Figliuolo F, De Luca F, Mele F, Tommasi S, Strippoli S. Guida M, et al. Among authors: bartolomeo n. Cancers (Basel). 2019 Oct 14;11(10):1559. doi: 10.3390/cancers11101559. Cancers (Basel). 2019. PMID: 31615127 Free PMC article.
No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study.
Guida M, Bartolomeo N, Quaglino P, Madonna G, Pigozzo J, Di Giacomo AM, Minisini AM, Tucci M, Spagnolo F, Occelli M, Ridolfi L, Queirolo P, De Risi I, Quaresmini D, Gambale E, Chiaron Sileni V, Ascierto PA, Stigliano L, Strippoli S, On Behalf Of The Italian Melanoma Intergroup Imi Study. Guida M, et al. Among authors: bartolomeo n. Cancers (Basel). 2021 Jan 26;13(3):475. doi: 10.3390/cancers13030475. Cancers (Basel). 2021. PMID: 33530579 Free PMC article.
MC1R genotype and psoriasis: is there a link revealing a phenotypic difference?
Guida S, Foti C, Manganelli M, Bartolomeo N, Pellacani G, Bonamonte D, Filotico R, Guida G. Guida S, et al. Among authors: bartolomeo n. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):e119-e120. doi: 10.1111/jdv.14607. Epub 2017 Oct 16. J Eur Acad Dermatol Venereol. 2018. PMID: 28960463 No abstract available.
87 results